RA Capital Management, L.P. Files Schedule 13G for Lexeo Therapeutics, Inc.

RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., filed a Schedule 13G with the SEC on October 27, 2025, disclosing beneficial ownership of 5,000,000 shares of common stock in Lexeo Therapeutics, Inc. This represents 6.9% of the company's outstanding shares. The filing indicates that RA Capital Healthcare Fund, L.P. directly holds the shares, while RA Capital Management, L.P. serves as the investment adviser for the fund. The filing also notes that RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities except for the purpose of determining their obligations under Section 13(d) of the Act. The filing was made pursuant to Rule 13d-1(c) and includes a Joint Filing Agreement among the parties.